Showing results (291-300 of 324) with videos related to
Sort By:
Pageof 33
Scientific Reports|October 12, 2019
The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcomaA T J Lee, W Chew, C P Wilding, et al.European Journal of Cancer (Oxford, England : 1990)|March 11, 2004
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma GroupM Debiec-Rychter, H Dumez, I Judson, et al.British Journal of Cancer|September 1, 1993
A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancerE G de Vries, J A Gietema, P Workman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma GroupA Le Cesne, I Judson, D Crowther, et al.Clinical Oncology (Royal College of Radiologists (Great Britain))|March 19, 2018
European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic TherapyN Touati, P Schöffski, S Litière, et al.European Journal of Cancer (Oxford, England : 1990)|September 1, 2015
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trialsF Duffaud, S Sleijfer, S Litière, et al.British Journal of Cancer|October 27, 2005
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026B P Nutley, N F Smith, A Hayes, et al.International Journal of Radiation Oncology, Biology, Physics|November 25, 2003
Uterine sarcoma: twenty-seven years of experienceL Livi, F Paiar, N Shah, et al.British Journal of Cancer|August 15, 2013
Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRIM Beloueche-Babari, Y Jamin, V Arunan, et al.British Journal of Cancer|October 2, 2003
In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotopeD R Collingridge, M Glaser, S Osman, et al.Pageof 33